TST003 News - LARVOL Sigma

|||||||||| TST003 / Transcenta
A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_7975;
P1/2
The enrollment is ongoing in clinical centers in the US and China. No significant safety signals were reported in the first few patients treated with TST003.Clinical Trial Information: NCT05731271.Study Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.

|||||||||| TST003 / Transcenta
The preclinical characterization of TST003, a first-in-class mAb targeting gremlin-1 overexpressed by cancer-associated fibroblasts and tumor cells (Section 16; Poster Board #29) - Mar 14, 2023 - Abstract #AACR2023AACR_2475;
In summary, TST003 is a first-in-class therapeutic mAb targeting Gremlin-1 overexpressed by CAFs and tumor cells. Our preclinical characterization results provided the rationale for on-going clinical evaluation of TST003 in patients with advanced solid tumors with high unmet medical need either as monotherapy or in combination with SoC.

||||||||||  TST003 / Transcenta
Enrollment open, Metastases:  A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov) -  Feb 17, 2023
P1/2, N=76, Recruiting,  Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
Our preclinical characterization results provided the rationale for on-going clinical evaluation of TST003 in patients with advanced solid tumors with high unmet medical need either as monotherapy or in combination with SoC. Not yet recruiting --> Recruiting

||||||||||  TST003 / Transcenta
New P1/2 trial, Metastases:  A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov) -  Feb 16, 2023
P1/2, N=76, Not yet recruiting,  Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.



	Diseases Companies Products Productz Mechanisms of Action Sites